Blood · 2000 · 37 citations · 47 references
Life SciencesCell BiologyImmunologyCancer ImmunologyCutaneous OncologyTumor ImmunologyCancer ImmunotherapyCutaneous LymphomaHelper T Cell SubsetsLymphoid NeoplasmsT Cell BiologyT Cell DifferentiationCd4 Positive T CellsCd4+ T Helper Cell ResponsesCd8 Positive T CellsCutaneous T-cell Lymphoma ImmunopathologyT Helper Cell Development
CDR3 of the functional rearranged T-cell receptor variable beta region (TCR-Vbeta) transcript was sequenced in order to demonstrate for the first time the identity between a long-term cultured T-cell line derived from a cutaneous T-cell lymphoma (CTCL) patient and the malignant T-cell clone present in the blood. The patient's peripheral blood lymphocyte-derived cultured T-cell line had a CD3(+)Vbeta22(+)CD4(+)CD8alphaalpha(+)CD25(-) phenotype. It was named Pno and had been cultured for more than 1 year. Both fresh and long-term-cultured tumor cells proliferated highly in response to interleukin-7 (IL-7), and exogeneous IL-7 prevented Pno lymphocytes from apoptosis and maintained high levels of Bcl-2 expression. This unique malignant cloned lymphocyte line was further used to carry out functional studies. The results indicated that the CD3/TCR structures expressed by the Pno lymphocytes were functional because an immobilized anti-CD3 monoclonal antibody (mAb) or the combination of a soluble anti-CD3 mAb with submitogenic doses of phorbol 12 beta-myristate 13 alpha-acetate induced a proliferative response. Further, the CD2 and CD28 coreceptors were functional because they were able to induce a strong proliferative response upon their specific stimulation. Finally, the Pno T cell line had a Th3-type cytokine profile because it produced high amounts of the immunosuppressor cytokine tumor growth factor-beta1 (TGF-beta1). This high production of TGF-beta1 may inhibit antitumor specific responses in CTCL.
47
A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
Hervé Groux, Anne O’Garra, Mike Bigler et al. · Nature · 1997 · 3.6K citations
Life Sciences, Immunology, Pathology +12
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
Gerrit Koopman, CP Reutelingsperger, GA Kuijten et al. · Blood · 1994 · 2.5K citations · Full text
Medicine, Cell Biology, Pathology +11
Gerrit Koopman, CP Reutelingsperger, GA Kuijten et al. · Blood · 1994 · 2.1K citations
Medicine, Cell Biology, Pathology +11